The global dengue treatment market was valued at US$ 296 Million in 2019 and is projected to reach US$ 727 Million by 2027 expanding at a CAGR of 13.3 % during the forecast period, 2021-2027. Dengue is the most rapidly spreading mosquito-borne viral disease in the world. Dengue fever, also known as break-bone fever, leads to severe flu. Dengue is caused by an RNA virus of mosquitos that belong to the Flaviviridae family and several other species of mosquitos such as Aedes. Symptoms of dengue include fever, headache vomiting, muscle, joint pain, and characteristic skin rash. The patient recovers from dengue within seven days; however, in some cases, it can develop into life-threatening dengue hemorrhagic fever. The global dengue treatment market is anticipated grow due to the rise in the burden of dengue in tropical and subtropical regions. Increase in government funding to fight against dengue and unmet market needs of managing this burden globally boosts the dengue treatment market.
Request Free Sample Report Here
Market Dynamics
The market is driven by factors such as growing awareness about prevention and control of dengue, robust promising pipeline of manufacturers for dengue treatment, increasing prevalence of dengue. However, stringent government regulations regarding drug approval, and lack of government facilities and skilled medical professionals in under developed countries are the factors expected to hamper the market growth. Whereas, rising R&D investment and activities is expected to create lucrative opportunities in the market.
Segmental Outlook
On the basis of type, the global dengue treatment market is bifurcated into drug and vaccine. The drug segment is expected to holds a major share of the market, in terms of volume, due to easy availability and low cost prices.
Based on route of administration the global dengue treatment market is classified into oral, and parenteral. The parenteral segment is projected to hold a major share of the market due to their high cost and wide adoption, as patients need instant recovery from the dengue virus. This, in turn, increases the demand for the vaccine using parenteral route of the administration during the forecast period.
Regional Outlook
In terms of region the market has been fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is a promising region for the market. It constituted around half of the market in terms of share in 2019. The market in the region is projected to expand at a CAGR of 14.0 % during the forecast period. The demand for dengue treatment is expected to rise due to the rapid increase in prevalence of dengue in the region during the forecast period.
Competitive Landscape
Key players in the market include Sanofi, and Johnson & Johnson Services, Inc. These companies are considered as key manufacturers of dengue treatment based on their revenue, research development (R&D) activities, product offerings, regional presence, and supply chain management system.
The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunity for the dengue treatment extraction is added in the company’s capacity.
About Growth Market Reports:
GROWTH MARKET REPORTS provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Industry Intelligence Solutions”. GROWTH MARKET REPORTS has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.
Contact:
Growth Market Reports
Phone: +1 909 414 1393
Email: [email protected]
Web: https://growthmarketreports.com
Best Hospitals for Dengue Fever Treatment in India.
Dengue fever, otherwise called breakbone fever, is a mosquito-borne disease that can prompt an extreme flu-like sickness.
It is caused by four distinctive viruses and spread by Aedes mosquitoes.
Millions of cases of dengue happen worldwide every year.
Dengue fever is most prevalent in Southeast Asia and the western Pacific islands Contact us for more information.
Dengue Drugs Market OverviewDengue Drugs Market is expected to grow at a CAGR of 2.6% from 2019 to 2030Insightful data based on Dengue Drugs Market has been recently published by Absolute Markets Insights.
The report provides profound information on effective analysis of the businesses.
Moreover, the report uses an exploratory technique such as qualitative and quantitative analysis to discover the data of the market in question.
For instance, Indian Ministry of Science and Technology in partnership with Sun Pharmaceutical Industries Ltd. developed an herbal medicine for dengue in 2019.
Similarly, 60 Degrees Pharmaceuticals of Singapore was granted a patent for a novel dengue drug named Celgosivir in 2014.Access Full Report Details and Order this Premium Report @ https://www.absolutemarketsinsights.com/reports/Reusable-Shipping-Boxes-Market-2019-2030-617 Top Key Venders of Market:For instance, Indian Ministry of Science and Technology in partnership with Sun Pharmaceutical Industries Ltd. developed an herbal medicine for dengue in 2019.
These on-going developments of newer drugs are anticipated to drive the global dengue drugs market in forecast years.
Dengue Vaccines Market: IntroductionAccording to the report, the global dengue vaccines market was valued at US$ 0.4 Bn in 2020 and is projected to expand at a CAGR of 11% from 2021 to 2031.
Dengue is a mosquito-borne tropical disease caused by dengue virus.
These include high fever, vomiting, headache, muscle & joint pain, and a characteristic skin rash.
The World Health Organization recommends that the vaccine should only be given to persons with confirmed prior history of dengue virus infection.
The vaccine manufacturer, Sanofi Pasteur, announced in 2017 that people who receive the vaccine and have not previously infected by the virus could be at risk of developing severe dengue, if they are infected after being vaccinated.Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=28397Disrupted sanitation services and curtailed water supply lead to conditions that assist mosquito breeding and proliferation, while warm temperatures lead to longer active season for mosquitos.
The region offers significant opportunities in the dengue vaccines market.Increase in Incidence of Dengue to Drive Dengue Vaccines MarketThe number of cases of dengue has increased over the past few years.
Growth of the global dengue vaccine market is mainly driven by rising burden of dengue fever in tropical regions, large unmet medical need for managing dengue burden, promising end stage vaccine pipeline, development of live attenuated tetravalent dengue vaccine and expected local production of dengue vaccine in various countries are expected drive the market over forecasted period.Other prominent factors driving growth of the market are adoption/uptakeof dengue vaccine by various countries in dengue endemic regions of Latin America and Asia Pacific and increased governments interest to incorporate the vaccine in public immunization programmes in various countriesHowever, supply side infrastructure bottle necks such as surveillance system, standardized diagnostics practice, and cold chain systems for storage of vaccine in resource constrained countriesare the factors suggestive of barrier to growth of global Dengue Vaccinemarket.Players in thedengue vaccine development and in market are employing strategies to incorporate dengue vaccine in public immunization programs and vaccines in clinical stage development are being tested for safety and efficacy in all age groups and different transmission settings.
Request For Report Sample: https://www.researchreportinsights.com/report/sample/110114999/Dengue-Vaccine-Market Market SegmentationbyEnd UserBased on end user, the market has been segmented into hospitals, government institutes, and Non-Governmental Organizations (NGOs).
In terms of value, government institutesegment is estimated to account for more than 51.9% market share in global dengue vaccine market, by 2027 end.Key RegionsThe global Dengue Vaccinemarket has been segmented into four major regions:Latin America, Asia Pacific, Middle East & Africa (MEA), and Rest of the World (RoW).
In terms of value, the Asia Pacific markethas been estimated to dominate the global dengue vaccine market in 2017,and is expected to expand at a CAGR of 17.4% over the forecast period.
Latin America isexpected to be the fastest growing markets among regional markets.
Latin Americamarket is expected to witness highest CAGR of 18.0% over the forecast period.
